Clinical Trials List
2022-03-31 - 2027-12-31
Phase III
Recruiting6
ICD-10C22.0
Liver cell carcinoma
ICD-10C22.2
Hepatoblastoma
ICD-10C22.3
Angiosarcoma of liver
ICD-10C22.4
Other sarcomas of liver
ICD-10C22.7
Other specified carcinomas of liver
ICD-10C22.8
Malignant neoplasm of liver, primary, unspecified as to type
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.0
Malignant neoplasm of liver, primary
A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-3)
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Chung-Pin Li Digestive System Department
- San-Chi Chen Division of Hematology & Oncology
- Pei-Chang Lee Digestive System Department
- Yi-Ping Hung Division of Hematology & Oncology
- I-Cheng Lee Digestive System Department
- Ming-Huang Chen Division of Hematology & Oncology
- Chien-An Liu Division of Radiology
- Yi-Hsiang Huang Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 呂理駿 Division of Hematology & Oncology
- Shih-Jer Hsu Division of General Internal Medicine
- Chien-Hung Chen Division of General Internal Medicine
- 蘇東弘 Division of General Internal Medicine
- Ming-Chih Ho Division of General Surgery
- YU-YUN SHAO Division of Hematology & Oncology
- Chiun Hsu Division of Hematology & Oncology
- Ann-Lii Cheng Division of Hematology & Oncology
- Ying-Chun Shen Division of Hematology & Oncology
- 楊宏志 Division of General Internal Medicine
- 林宗哲 Division of Hematology & Oncology
- - - Division of Radiology
- TSUNG-HAO LIU Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ming-Mo Hou Division of Hematology & Oncology
- Yi-Chung Hsieh Digestive System Department
- 周宏學 Division of General Surgery
- Shi-Ming Lin Digestive System Department
- Chia-Hsun Hsieh Division of Hematology & Oncology
- 呂嘉偉 Division of Radiology
- 林伯庭 Digestive System Department
- 陳威廷 Digestive System Department
- Wei-Chen Lee Digestive System Department
- Chun-Yen Lin Digestive System Department
- 滕威 Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Wei-Fan Hsu Digestive System Department
- Po-Heng Chuang Digestive System Department
- Hung-Wei Wang Digestive System Department
- Cheng-Yuan Peng Digestive System Department
- Hsueh-Chou Lai Digestive System Department
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chiu Hung Chiu Digestive System Department
- 邱彥程 Digestive System Department
- Liu Yi-Sheng Division of Radiology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
靜脈點滴注射劑
Active Ingredient
Tremelimumab
Dosage Form
242
Dosage
20mg
Endpoints
Inclution Criteria
No evidence of extrahepatic disease
Disease not amenable to curative surgery or transplantation or curative ablation but disease amenable to TACE
Child Pugh score class A
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment
Measurable disease by Modified Response Criteria in Solid Tumors (mRECIST) criteria
Adequate organ and marrow function
Exclusion Criteria
History of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardia arrhythmia
History of hepatic encephalopathy
Major portal vein thrombosis visible on baseline imaging
Uncontrolled arterial hypertension
Co-infection with HBV and HDV
The Estimated Number of Participants
-
Taiwan
60 participants
-
Global
725 participants
